Track market-moving stories before they get noisy

California Public Employees Retirement System cut its holdings in shares of Henry Schein, Inc. (NASDAQ: HSIC) by 14.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 246,925 shares of the company's stock after selling 43,137 shares during the

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2026 financial results before the stock market opens on Tuesday, August 4, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Fred Lowery, Chief Executive Officer and.

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

One company to watch right now is Henry Schein (HSIC - Free Report) . HSIC is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock holds a P/E ratio of 13.27, while its industry has an average P/E of 16.98. HSIC's Forward P/E has been as high as 15.82 and as low as 12.57, with a median of 13.90, all within the past year.

We should also highlight that HSIC has a P/B ratio of 2.01. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 5.38. Over the past 12 months, HSIC's P/B has been as high as 2.53 and as low as 1.92, with a median of 2.16.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. HSIC has a P/S ratio of 0.74. This compares to its industry's average P/S of 1.39.

Finally, our model also underscores that HSIC has a P/CF ratio of 11.89. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 17.91. Over the past 52 weeks, HSIC's P/CF has been as high as 15.66 and as low as 10.92, with a median of 12.77.

These are only a few of the key metrics included in Henry Schein's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, HSIC looks like an impressive value stock at the moment.

Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. “I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins. Our growth outlook, combined with the progress made on value-creation initiatives.

Henry Schein (HSIC - Free Report) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +10.30%. A quarter ago, it was expected that this health care products maker would post earnings of $1.3 per share when it actually produced earnings of $1.34, delivering a surprise of +3.08%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Henry Schein, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $3.37 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.15%. This compares to year-ago revenues of $3.17 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Henry Schein shares have lost about 4.7% since the beginning of the year versus the S&P 500's gain of 5.2%.

What's Next for Henry Schein?While Henry Schein has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Henry Schein was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.19 on $3.37 billion in revenues for the coming quarter and $5.30 on $13.69 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Becton Dickinson (BDX - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This medical device manufacturer is expected to post quarterly earnings of $2.77 per share in its upcoming report, which represents a year-over-year change of -17.3%. The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level.

Becton Dickinson's revenues are expected to be $4.67 billion, down 11.5% from the year-ago quarter.

For the quarter ended March 2026, Henry Schein (HSIC - Free Report) reported revenue of $3.37 billion, up 6.3% over the same period last year. EPS came in at $1.32, compared to $1.15 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.33 billion, representing a surprise of +1.15%. The company delivered an EPS surprise of +10.3%, with the consensus EPS estimate being $1.20.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Henry Schein performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- International Distribution and Value-Added Services- Dental: $900 million versus the four-analyst average estimate of $857.3 million. The reported number represents a year-over-year change of +12.8%.Geographic Revenue- International Distribution and Value-Added Services- Medical: $30 million compared to the $26.86 million average estimate based on four analysts. The reported number represents a change of +20% year over year.Geographic Revenue- U.S. Distribution and Value-Added Services: $1.91 billion compared to the $1.91 billion average estimate based on four analysts.Geographic Revenue- U.S. Distribution and Value-Added Services- Dental- Merchandise: $624 million versus $604.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.6% change.Net Sales- Global Specialty Products: $397 million versus $398.74 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change.Net Sales- Global Technology: $173 million versus $173.27 million estimated by six analysts on average.Net Sales- Global Distribution and Value-Added Services: $2.84 billion compared to the $2.8 billion average estimate based on six analysts.Net Sales- Eliminations: $-41 million versus the six-analyst average estimate of $-40.66 million. The reported number represents a year-over-year change of +10.8%.Net Sales- Global Distribution and Value-Added Services- Global Dental: $1.77 billion versus the four-analyst average estimate of $1.7 billion.Net Sales- Global Distribution and Value-Added Services- Global Medical: $1.07 billion compared to the $1.09 billion average estimate based on four analysts.Geographic Revenue- International Distribution and Value-Added Services: $930 million compared to the $884.16 million average estimate based on four analysts.Net Sales- Global Distribution and Value-Added Services- Global Dental- Global Equipment: $417 million versus $411.03 million estimated by four analysts on average.View all Key Company Metrics for Henry Schein here>>>

Shares of Henry Schein have returned -3.8% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Henry Schein (HSIC - Free Report) Melville, NY-headquartered Henry Schein Inc. is a leading distributor of health care products and services across the globe. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein operates in 34 countries.

HSIC is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 14.04; value investors should take notice.

One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.00 to $5.30 per share. HSIC also boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, HSIC should be on investors' short list.

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.

Henry Schein NASDAQ: HSIC executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.

Speaking at a Bank of America healthcare technology and distribution event, Chief Executive Officer Fred Lowery, who has been in the CEO role for about two months, said the company had a “good Q1,” citing healthy growth in dental, strong growth in technology and distribution, and margin expansion during the quarter. Lowery said medical was softer, but that excluding flu-related impacts, underlying performance was “pretty good,” with mid-single-digit growth.

Lowery said Henry Schein recommitted to delivering a $125 million net run-rate value creation benefit by the end of the year and $200 million over the next several years. He also said the company reconfirmed its 2026 guidance.

Get Henry Schein alerts:

CEO Focuses on Customers, AI and Commercial Alignment Lowery said his first 100 days are centered on learning the business through meetings with customers, suppliers and employees, whom the company refers to as “Team Schein” members. He said he is assessing current projects and evaluating where the company should invest for future growth.

One area of focus is artificial intelligence, which Lowery said could help accelerate new product development and improve capabilities brought to market, particularly in Henry Schein’s technology business. He also pointed to commercial alignment as an opportunity, saying the company wants to present customers with a broader value proposition across multiple parts of Henry Schein.

Lowery said the company is working to shift its customer message from helping customers save money to helping them “make more money,” grow faster and operate more productively.

Operational Savings Expected to Build in Second Half Chief Financial Officer Ron South said the $125 million target represents the expected net run-rate operating income improvement as the company enters 2027. He said Henry Schein expects some benefit in 2026, with savings more weighted toward the second half of the year.

South said the timing is largely due to general and administrative initiatives, which require planning and structural changes in how the company supports the business. He said the goal is to create a scalable structure that can support growth without adding significant incremental cost.

Gross profit optimization is expected to contribute sooner, South said, with some benefit already seen in the first quarter. He cited dynamic pricing as one example, adding that it does not only mean increasing prices but can also include lowering prices in areas where Henry Schein wants to be more competitive.

Dental Momentum Continues; Medical Growth Excluding Diagnostics South said dental momentum seen in April continued into May. He said achieving the company’s desired dental growth requires taking market share, which includes retaining current customers and reducing churn.

In medical, South said point-of-care diagnostic kit sales weighed on first-quarter growth because demand for those products is tied to the respiratory illness season, including flu and RSV. Excluding that category, he said the medical business grew in the mid-single digits.

South said the diagnostic kit category is typically more important in the fourth and first quarters, so he expects less impact in the middle of the year. He also highlighted Henry Schein’s home solutions business, which he said now accounts for more than 10% of medical revenue, with a run rate of more than $400 million. He said the business grows faster and has better margins than core medical.

Margins Supported by Private Label and Pricing Tools South said gross margin improvement in distribution reflected early benefits from gross profit optimization, stability in glove pricing and faster growth in company-owned brands, or private label products. He said those products carry better gross margins than the overall portfolio and that he believes the margin level can be sustainable.

Asked about exposure to oil-linked inputs, South said some product categories may be affected by petroleum-based materials. He said Henry Schein can consider price increases where needed, redirect customers to similar products with less cost pressure, or use private label alternatives where available. He compared the approach to how the company managed tariff volatility last year.

South also noted that oil prices can affect freight costs. He said the company is working with customers to explain any fuel surcharges where needed and believes its approach remains in line with the market.

DSO, Specialty and M&A Opportunities Lowery said he has met with many of Henry Schein’s largest dental service organization customers and some smaller DSOs. He said those customers see value in Henry Schein and believe there is more the parties can do together.

Lowery identified corporate brands and practice management software as areas of opportunity with DSOs. He said the company expects to expand corporate brand share with DSOs over multiple years rather than through a quick, one-time shift.

In specialty, South said the segment grew about 8%, while local internal growth was 1.7%, a rate the company expects to improve as the year progresses. In the U.S. implant market, he said value implants continue to grow faster than premium implants, both in the market and in Henry Schein’s portfolio. He said the company’s acquisition of the S.I.N. U.S. distributor gives it greater control over that portfolio.

South said Henry Schein will remain disciplined on mergers and acquisitions, with a focus on higher-growth, higher-margin areas such as specialty products, technology and value-added services. He said home solutions also remains an area for potential fold-in acquisitions because it is growing faster and has higher margins than the company’s core medical business.

Lowery said he will measure success over the next year by whether Henry Schein delivers on its 2026 guidance, achieves its value creation commitments and develops a clearer line of sight toward accelerating growth more profitably as an extension of its BOLD+1 Strategy.

About Henry Schein NASDAQ: HSICHenry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Henry Schein Right Now?Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Henry Schein (HSIC - Free Report) Melville, NY-headquartered Henry Schein Inc. is a solutions company for health care professionals that combines distribution, technology, and value-added services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein operates in 34 countries and offers a comprehensive selection of more than 300,000 branded products.

HSIC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 13.83; value investors should take notice.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.01 to $5.31 per share. HSIC also boasts an average earnings surprise of +3.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, HSIC should be on investors' short list.

Key Takeaways HSIC benefits from a broad dental and medical distribution network and revenue growth driven by acquisitions.HSIC's growth is supported by digital dentistry adoption, AWS collaboration and distribution agreements.HSIC faces leverage and macroeconomic pressures, including debt load, inflation and cost volatility. Henry Schein, Inc. (HSIC - Free Report) is well-poised to grow in the coming quarters due to its scale in dental and medical distribution. The company’s revenue expansion has been consistently supported by niche acquisitions and partnerships. The rising adoption of digital imaging and chairside workflows backs Henry Schein’s global digital dentistry push and can drive continued attachment of equipment, service and supplies. Yet, headwinds from macroeconomic factors and a debt-heavy balance sheet raise concerns. 

Over the past year, this Zacks Rank #3 (Hold) stock has climbed 5.2% compared with the 3.3% growth of the industry and the 31.4% rise of the S&P 500 composite.

The leading distributor of healthcare products and services has a market capitalization of $8.42 billion. The company’s earnings are expected to rise 7% in 2026 compared with the industry’s 5.1% growth. In the trailing four quarters, the company delivered an average earnings surprise of 3.74%.

Let’s delve deeper.

HSIC’s TailwindsWidespread Network and Channel Mix: Henry Schein’s distribution footprint supports broad customer coverage and operating efficiency across dental and medical markets. Apart from North America, the company has a presence in Australia and New Zealand, as well as in emerging nations like China, Brazil, Israel, the Czech Republic and Poland. In 2025, it also expanded its wide range of solutions and services in the Hawaiian Islands through the acquisition of R. Weinstein, Inc. In the first quarter of 2026, Global Distribution and Value-Added Services generated $2.84 billion of net sales, up 2.5% year over year. Management reaffirmed 2026 total sales growth guidance of about 3% to 5%, which keeps the focus on leveraging scale, service levels and supplier relationships to gain share over time.

Image Source: Zacks Investment Research

Expansion Through Acquisitions, Partnerships and Value Creation: Henry Schein’s acquisition strategy is to pursue targets that add product capabilities and expand its access to faster-growing categories. In first-quarter 2026, acquisitions contributed 0.7% to total net sales growth. The company also acquired a controlling interest in its S.I.N. distributor in the United States to enhance its position in the value implant market and support its business integration strategy.

In 2025, Henry Schein expanded its agreement with vVARDIS to become the exclusive U.S. distributor of the drill-free Curodont Repair Fluoride Plus product across all dental market segments. The company has also been investing in technology partnerships, including its collaboration with Amazon Web Services to integrate generative AI across the Henry Schein One ecosystem, and launched LinkIt to improve digital workflow connectivity for Dentrix users.
Alongside these growth initiatives, management is advancing its value creation program, recording $12 million of restructuring expense in first-quarter 2026 as the company executes on its operational plan.

Dental Business Trends Seem Favorable for the Long Term: As dentistry adopts digital imaging and chairside workflows, Henry Schein’s efforts to expand digital dentistry globally can support continued attachment of equipment, service and supplies. The company sells its consumable merchandise and manufactures specialty products in implants, orthodontics and endodontics, which helps it address a wider range of practice needs.

In the first quarter of 2026, Global Dental’s net sales were $1.77 billion, up 3.2% year over year. Management noted that dental practices and DSOs continued to invest in equipment and that the backlog in traditional equipment remained healthy. Dental procedure volumes held steady despite higher merchandise prices, which is consistent with a stable demand environment. In Specialty Products, value implant systems grew in the high single-digits, with improved growth projected in the segment as the year progresses. Premium implants were supported by clinical engagement and new product launches.

What Ails HSIC Stock?Weak Solvency: Henry Schein ended the first quarter of 2026 with cash and cash equivalents of $138 million, down from $156 million at the end of fourth-quarter 2025. The balance sheet remains levered, with current debt of $1.08 billion and long-term debt of $2.33 billion. At quarter-end, the debt-to-capital ratio was 37.6%, while times interest earned was 4.5X.

Macroeconomic Challenges: The company remains exposed to swings in inflation, foreign exchange and freight costs that can affect demand and profitability. In first-quarter 2026, adjusted operating margin increased 28 basis points year over year to 7.53% on gross margin expansion and mix, yet cash flow was seasonally negative. Henry Schein’s 2026 guidance assumes stable dental and medical end markets and that tariff changes and higher oil prices can be mitigated, but it also signals that product pricing and shipping costs are moving parts.

HSIC Stock Estimate TrendThe Zacks Consensus Estimate for HSIC’s 2026 earnings per share (EPS) has moved to $5.32 from $5.30 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $13.72 billion. This suggests a 4.1% rise from the year-ago reported number.

 Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 40.2% against the industry’s 7.7% fall over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Align Technology, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 10.3% for fiscal 2026 compared with the industry’s 9.5% growth. Shares of the company have dropped 11% compared with the industry’s 3.3% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.7% against the industry’s negative 15.7% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 19.9% against the industry’s 7.6% decline over the past year.

Henry Schein NASDAQ: HSIC executives said the company is on track with its 2026 commitments and value-creation plan, while pointing to continued momentum in the U.S. dental market despite broader concerns about consumer confidence.

Speaking at a Stifel dental track event moderated by Stifel Managing Director Jon Block, Fred Lowery, who became Henry Schein’s chief executive officer in March, said his first roughly 100 days have been focused on “listening and learning” and organizing priorities into three areas: delivering on commitments, simplifying the business and scaling for growth.

Lowery said Henry Schein remains on track to deliver on its 2026 guidance and previously outlined value-creation initiatives. He also said the company has opportunities to simplify a decentralized business structure, including joint ventures and aspects of its commercial approach, while building on its technology, own-brand and distribution capabilities.

Get Henry Schein alerts:

Dental Demand Remains Steady Lowery said the dental market has remained relatively steady because a large portion of dental demand is tied less to consumer sentiment and more to employment and insurance coverage.

He described two major groups of patients: those who visit the dentist every six months, often with employer-provided insurance, and those who delay treatment until pain, discomfort or visible issues require care. Lowery said a smaller portion of the market is more discretionary, including cosmetic procedures.

“As long as people are working at a reasonable rate, and unemployment rates have been pretty steady, I think that bodes well for the market overall,” Lowery said.

Ron South, Henry Schein’s senior vice president and chief financial officer, said the company saw dental momentum improve through the first quarter, with February better than January and March better than February. He said that momentum continued into April and through the first part of May.

South said Henry Schein has not yet seen a direct correlation between recent weaker consumer confidence measures and its dental business. He attributed the company’s improvement in dental to momentum that began in the third quarter of last year, including promotional activity in mid-2025 that helped the company gain market share in the second half of that year.

South said Henry Schein has moved “a little more on offense” and is seeing benefits from hiring experienced sales representatives and emphasizing its role as a solutions provider rather than only a product provider.

Medical and International Trends Lowery said Henry Schein’s medical business faced pressure in the first quarter from diagnostic test kits tied to respiratory illness, primarily flu. Excluding that headwind, he said the underlying medical business grew at a mid-single-digit rate, and that trend has continued into the second quarter.

Lowery also highlighted strong growth in the company’s home solutions business.

On international markets, South said Germany has remained a steady market for Henry Schein in core dental and specialty. He also cited Canada as a strong business that has managed competitive challenges well.

Revenue Growth and New Products South said first-quarter overall revenue growth benefited by about three points from foreign exchange, a benefit he expects to diminish as the year progresses. He said the company expects to improve its internal growth rate after first-quarter headwinds from point-of-care diagnostic kits in medical and timing in the specialty business.

Lowery said Henry Schein continues to expect suppliers to invest in new products and views its distribution network as an attractive launch platform. He pointed to Curodont, which he said is being launched exclusively through Henry Schein’s distribution network, as an important product in the company’s portfolio.

Lowery also said Henry Schein is accelerating new capabilities in its technology business, including through internal artificial intelligence development and partnerships that can plug into its clinical workflow and practice management systems. He said investors should expect a “steady drumbeat” of new products and capabilities in technology, along with continued product launches in specialty products.

In implants, Lowery said Henry Schein became the majority owner of the S.I.N. U.S. distribution business in the first quarter. He described S.I.N. as a value implant business operating in a part of the U.S. market where growth is strong.

Value-Creation Plan Lowery said Henry Schein’s value-creation plan is broader than cost reduction and includes gross profit improvement and operating efficiency. He said the company is investing in analytics, tools and personnel to improve pricing visibility and make more targeted decisions on where to raise or lower prices.

He said Henry Schein is also focused on expanding its own brands and building shared-service capabilities for back-office functions with an outsourced partner. Lowery added that the company is developing systems, processes and personnel to better leverage its scale in indirect sourcing.

Lowery said the company has line of sight to a $125 million net run-rate operating income improvement by the end of 2026 and expects to deliver up to $200 million over the next few years.

South said the $125 million run-rate target supports the possibility of double-digit earnings growth in 2027, though he said it is too early to provide 2027 guidance.

Portfolio, Equipment and Capital Allocation Lowery said Henry Schein is comfortable with the current perimeter of its business, including the medical segment. He said the medical and dental businesses are integrated from a supply chain standpoint, with about 30% of SKUs overlapping between the two.

On dental equipment, South said Henry Schein’s U.S. equipment mix remains roughly two-thirds traditional equipment and one-third digital equipment. He said lower average selling prices for intraoral scanners may encourage more dental practices to adopt digital technology, potentially creating future opportunities for additional digital equipment sales.

Lowery said Henry Schein remains committed to a balanced and disciplined capital allocation strategy. He said share repurchases have been prioritized recently and are likely to remain a priority in the near term because he believes the stock is undervalued.

Lowery said the company also wants to maintain flexibility for strategic investments and would approach mergers and acquisitions in a disciplined way, focusing on assets that support customers, drive future organic growth, expand margins and generate appropriate shareholder returns.

About Henry Schein NASDAQ: HSICHenry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Henry Schein Right Now?Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

© Chaay_Tee / iStock via Getty Images

Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The “Buy the Dip” traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to hit bids that have moved higher. The song remains the same: the war with Iran, inflation (which saw the Consumer Price Index jump to 4.2%), yields moving higher, and rotation out of the AI/Datacenter trade continue to keep the sellers coming back for more. With the gigantic SpaceX IPO set to trade on Friday, some of the selling could be to raise cash to pay for allocations, which should be big for institutions, but the reality is we could be on the edge of a much bigger sell-off. The Nasdaq was the biggest loser on the day, falling 1.98% to close at 25,169, while the Dow Jones Industrial Average was not far behind, ending the session at 49,918, down 1.87%. The S&P 500 closed at 7,266, down 1.62%, and the Russell 2000 was last seen at 2,835, down 1.10%.

Treasury Bonds: Yields were higher across the Treasury curve, but the selling pressure wasn’t as severe as in equity markets. The huge CPI print, while the highest in 3 years, was expected, as that is where estimates were. Had the estimate been dramatically lower, we would have likely seen much more selling pressure. The 30-year-long bond closed the day at 5.03%, while the benchmark 10-year note finished the day at 4.55%. 

Oil and Gas: Needless to say, with the possibility of the war with Iran ratcheting up, energy prices across the board moved higher on Wednesday. When the closing bell rang, Brent Crude’s final print was recorded at $94.60, up 3.44%, while West Texas Intermediate closed the session at $90.03, up 2.07%. Natural gas tagged along for the energy ride, finishing the day at $3.19, up 1.43%.

Gold: Gold had another tough day, and the trend for the precious metal is starting to look bad, as it hit its lowest level since last November. This selling trend follows reports that China bought +10 tonnes (a tonne is a metric reference, which is higher than the US ton) of gold in May, the largest monthly addition since January 2025. This follows +8 tonnes acquired in April, marking their 3rd consecutive monthly net purchase. China has now bought gold for 19 consecutive months, the longest streak since at least 2015, when its central bank began publishing more regular data on its gold reserves. The final trade for the precious metal on Wednesday came in at $4070.30, down 4.42%, while Silver was last seen at $62.25, down 2.95%. 

Crypto: Cryptocurrencies endured a volatile Wednesday, with Bitcoin sliding to around $61,000 as the broader market grappled with a cooling AI sector and persistent institutional outflows. Although prices received an early lift from softer-than-expected U.S. inflation data, overall sentiment stayed firmly under pressure. At 8 AM EDT, Bitcoin was trading at $63,050, while Ethereum was trading at $1,665. 

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock. 

Here are some of the Best Wall Street analyst upgrades, downgrades, and initiations seen on Thursday, June 11, 2026.  

Upgrades: Black Hills (NYSE: BKH | BKH Price Prediction) was upgraded to Buy from Neutral at Bank of America, which nudged their target price to $78 from $76. The company is merging with Northwestern Energy in an all-stock deal. CME Group (NYSE: CME) was raised to Buy from Neutral by Rothschild & Co Redburn, which bumped the target price for the shares to $323 from $316. General Dynamics (NYSE: GD) was upgraded to Buy from Hold at Jefferies, which raised the price target for the Defense giant to $400 from $380. Henry Schein (NASDAQ: HSIC) was upgraded to Buy from Neutral at BTIG, with a $100 target price. Intel (NASDAQ: INTC) was double upgraded to Buy from Underperform at Bank of America, which raised the target price for the legacy chip giant to $135 from $96. Downgrades: Chewy (NYSE: CHWY) was downgraded to Neutral from Buy at MoffettNathanson, without a price target. J.Jill (NYSE: JILL) was cut to Market Perform from Outperform at William Blair, without a price target. MarketAxess Holdings (NASDAQ: MKTX) was cut to Neutral from Buy at Rothschild & Co Redburn, which slashed the price target for the shares to $134 from $189. Procept Biorobotics (NASDAQ: PRCT) was downgraded to Market Perform from Outperform at Leerink, which cut the target price for the stock to $29 from $31. Initiations: Callaway Golf (NYSE: CALY) was assumed in coverage with a Neutral rating at Goldman Sachs, which has set a $17 target price. Danaher (NYSE: DHR) was initiated with a Neutral rating at Piper Sandler, with a $200 target price objective. SpaceX (NASDAQ: SPCX) was started with no rating, but a $165 target price at New Street. Oppenheimer initiated coverage of the shares with an Outperform rating and a $190 target price. The massive IPO will start trading on Friday at $135. Rocket Lab USA (NASDAQ: RKLB) was started with a Neutral rating at KGI Securities, with a $105 target price. Toast (NYSE: TOST) was assumed with an Overweight rating at Piper Sandler, with a $32 target price.